Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Ortho_Clinical_Diagnostics
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Douglas_Bryant
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:founded |
1979
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quidel
|
| gptkbp:industry |
medical diagnostics
|
| gptkbp:notableProduct |
gptkb:QuickVue_At-Home_COVID-19_Test
gptkb:Sofia_SARS_Antigen_FIA |
| gptkbp:numberOfEmployees |
approximately 6,000 (2023)
|
| gptkbp:products |
diagnostic healthcare products
|
| gptkbp:publiclyTraded |
NASDAQ: QDEL
|
| gptkbp:specializesIn |
clinical chemistry
molecular diagnostics immunoassays point-of-care testing |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:QDEL
|
| gptkbp:website |
https://www.quidel.com/
|
| gptkbp:bfsParent |
gptkb:lateral_flow_assay
|
| gptkbp:bfsLayer |
6
|